Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and i...

Full description

Saved in:
Bibliographic Details
Main Authors: Vincenzo Montesarchio, Paolo Antonio Ascierto, Antonio Maria Grimaldi, Marcello Curvietto, Domenico Mallardo, Marco Palla, Chiara Iommelli, Antonella Bianco, Elio Manzillo, Fiorentino Fraganza, Cristiana Palumbo, Gaetano Rea, Patrizia Murino, Rosanna De Rosa, Luigi Atripaldi, Maurizio D’Abbraccio, Egidio Celentano, Claudia Trojaniello, Maria Grazia Vitale, Samuel Lewis Million-Weaver, Roberto Parrella
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001089.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001089.full

Similar Items